Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD; a Non-interventional Switch Study to Evaluate the Impact on Clinical Effects, Patient's Satisfaction, Preference and Use of Easyhaler
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms SUNNY
- Sponsors Orion; Orion Pharma
- 01 Oct 2019 Planned End Date changed from 1 Nov 2019 to 1 Feb 2020.
- 01 Oct 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Feb 2020.
- 06 Aug 2019 Planned End Date changed from 1 Sep 2019 to 1 Nov 2019.